AKBA Akebia Ther

USD 1.11 0.02 1.834862
Icon

Akebia Ther (AKBA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.11

+0.02 (+1.83)%

USD 0.23B

1.14M

USD 6.00(+440.54%)

USD 3.75 (+237.84%)

Icon

AKBA

Akebia Ther (USD)
COMMON STOCK | NSD
USD 1.11
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.23B

USD 3.75 (+237.84%)

USD 1.11

Akebia Ther (AKBA) Stock Forecast

Show ratings and price targets of :
USD 6.00
(+440.54%)

Based on the Akebia Ther stock forecast from 1 analysts, the average analyst target price for Akebia Ther is USD 6.00 over the next 12 months. Akebia Ther’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akebia Ther is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Akebia Ther’s stock price was USD 1.11. Akebia Ther’s stock price has changed by -1.77% over the past week, -8.26% over the past month and -11.90% over the last year.

No recent analyst target price found for Akebia Ther
No recent average analyst rating found for Akebia Ther

Company Overview Akebia Ther

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl...Read More

https://www.akebia.com

245 First Street, Cambridge, MA, United States, 02142

167

December

USD

USA

Adjusted Closing Price for Akebia Ther (AKBA)

Loading...

Unadjusted Closing Price for Akebia Ther (AKBA)

Loading...

Share Trading Volume for Akebia Ther Shares

Loading...

Compare Performance of Akebia Ther Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AKBA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Akebia Ther (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.75 (-0.36%) USD124.65B 31.35 20.00

ETFs Containing AKBA

Symbol Name AKBA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Akebia Ther (AKBA) Stock

Based on ratings from 1 analysts Akebia Ther's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on AKBA's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for AKBA is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on AKBA's stock to indicate if its overvalued.

The last closing price of AKBA's stock was USD 1.11.

The most recent market capitalization for AKBA is USD 0.23B.

Based on targets from 1 analysts, the average taret price for AKBA is projected at USD 6.00 over the next 12 months. This means that AKBA's stock price may go up by +440.54% over the next 12 months.

We can't find any ETFs which contains Akebia Ther's stock.

As per our most recent records Akebia Ther has 167 Employees.

Akebia Ther's registered address is 245 First Street, Cambridge, MA, United States, 02142. You can get more information about it from Akebia Ther's website at https://www.akebia.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...